Meeting Transcript
June 22, 2006
COUNCIL MEMBERS PRESENT
Edmund Pellegrino, M.D., Chairman
Georgetown University
Floyd E. Bloom, M.D.
Scripps Research Institute
Benjamin S. Carson, Sr., M.D.
Johns Hopkins Medical Institutions
Daniel W. Foster, M.D.
University of Texas, Southwestern Medical School
Michael S. Gazzaniga, Ph.D.
University of California, Santa Barbara
Alfonso Gómez-Lobo,
Dr.
phil.
Georgetown University
William B. Hurlbut, M.D.
Stanford University
Leon. R. Kass, M.D.
American Enterprise Institute
Peter A. Lawler, Ph.D.
Berry College
Paul McHugh, M.D.
Johns Hopkins University School of Medicine
Gilbert C. Meilaender, Ph.D.
Valparaiso University
Janet D. Rowley, M.D., D.Sc.
University of Chicago
Diana J. Schaub, Ph.D.
Loyola College
Carl E. Schneider, J.D.
University of Michigan
INDEX
- Session 1: Organ Transplantation and Procurement—the Empirical Context
- Session 2: Organ Transplantation and Procurement—Literary and
Philosophical-Anthropological Perspectives
- Session 3: Organ Transplantation and Procurement—The Ethical Challenges
- Session 4: Organ Transplantation and Procurement—Policy Proposals
WELCOME AND ANNOUNCEMENTS
CHAIRMAN PELLEGRINO: Good morning, this is one to
signal for those who are finishing their coffee that the time has come
to begin the meeting. We like to begin on time in deference to our
speakers, so they may address you fully. Good morning, if other
members of the Council will come in, we have a few more to go.
Good morning. Thank you, Alfonso, we're waiting for
you. Good morning, welcome to the 25th meeting of the
President's Council on Bioethics. My first official task which is
required each meeting is to note the presence of Dan Davis, Dr. Dan
Davis, the Executive Director of the Council. He's everybody's
boss, including mine and he is the official government representative
and, therefore, that gives the meeting its official status.
I want to welcome also a new council member, Dr. Carl
Schneider, Professor Schneider, who is Chauncey Stillman Professor for
Ethics, Morality and the Practice of Law at the University of
Michigan. In keeping with our custom, we do not go into long
introductions because the accomplishments of all those around the table
and the speakers far exceed any time we might have available to us in
one and a half days. So I hope they'll forgive me for this modesty
and it's no attempt to downgrade their accomplishments, I assure
you.
I also want to introduce two members of our research staff who
have just joined the council, Sam Crowe, who is a policy analyst
and Alan Rubenstein, who is a research analyst. Would those gentlemen
just stand so members of the Council — oh, they're coming
in. They're coming in together. It's not the Marx Brothers.
They don't have enough hair.
I would like also to indicate to you that the Council has
seven interns for the summer who work with various members of the
research staff, and perhaps they will be kind enough just to stand
briefly so we can see you and thank you very, very much. These young
interns come from various universities around the country and we're
delighted to have them. We're also pleased to have with us a
medical student from Georgetown, Paul Hutchison, who has spent a few
hours with me in tutorial but I assure you he's still in good
health. Paul, thank you very much.
SESSION 1: ORGAN TRANSPLANTATION AND PROCUREMENT—THE EMPIRICAL CONTEXT
We have a very full agenda and we don't want to cut
into the speakers in any way. So that I think we'll jump right
into the middle of the play. Our first speaker is Dr. Laura Siminoff,
who is Professor of Bioethics, Oncology and Family Medicine at Case
Western Reserve University. Dr. Siminoff.
DR. SIMINOFF: Okay, I use a Macintosh computer so
let's see if I can figure this — oh, somebody will figure it out
for me. So while they're figuring that out for me, what I wanted
to do today, what I was asked to do, was to summarize the issues in
organ donation. And essentially what I want to do is summarize what we
really know, what we empirically know and what you need to know, I
think, about how this process unfolds and what are important in terms
of consent and decision-making so that you can consider what I think is
a very important issue.
So I was told to do that with not too many slides, and I
was told to do that with not too many numbers. So I hope that I can
succeed. I want to assure you that everything I talk about actually is
backed up with numbers. So I'm going to talk about the — about
three factors that really impinge on what people decide to do about
organ donation and then the other thing I would like to do just really
briefly, if I have time and I think I'll have time, is to talk a
little bit about minorities and organ donation, because it's a
really critical problem in this country and I think it deserves some
very special attention from you.
And the other thing I want to talk about very, very quickly
is policy issues that we've sort of tried in this country and just
give you a little idea about how the general public feels about those
policies. So just to give you an overview, as you all probably know,
most Americans, if you ask them in a public opinion poll, you know,
"What do you feel about organ donation, are you positive, are you
negative, are you for it," at least 85 percent will say that they
personally are willing to donate organs.
Now, unfortunately, the numbers of people who actually
sign donor cards is much smaller, around 40 percent, if that. And what
we do know is that most people who become donors are brain dead
deceased patients, and no more than 50 percent of those eligible to do
so actually become donors. So you can see at each step of the way, we
lose people. So the other thing we know is that certain segments of
the population are less enthusiastic about donation. African Americans
and other minorities report that they're less positive about organ
donation than the majority white community, but I want to emphasize
even though they are not as enthusiastic, still the majority of African
Americans, Hispanics and Asians report that they would donate their
organs.
So the component to obtaining consent to organ donation are
the following. People have prior attitudes, knowledge and behaviors
about donation. There are issues around what happens between hospitals
and organ procurement organizations, that's the initials OPO and
I'll always be saying OPO so you'll know what that means. And
that's an issue because we have to recognize donor eligible
patients in order to actually consent somebody to donate.
And then the other big issue is what happens during the
request process. So the first component that we need to look at are
prior attitudes, knowledge and behaviors. Remember, people have two
different levels of thinking about this. It's ahead of time, what
would I do, as an individual? Should I sign a donor card, shall I mark
it off on my driver's license, so in that respect I can signify
formally my wishes. And the other issue is, should I tell somebody
what my wishes are? Should I tell my husband, my wife, my children
what I want to do? And most people have feelings about this.
We know from doing many, many surveys that when you talk to
the American public about organ donation, they don't say,
"What is that." Most people know what it is, 95 — at least
95 percent have heard of it and most people have given it at least a
little bit of thought. So there are a number of sociodemographic
factors that are associated with donation attitudes. As I mentioned,
minorities actually donate at half the rates of whites. Women, who act
as surrogate decision makers and remember, even though we may designate
ourselves as a donor on a driver's license, most of the time
it's our family surrogates, our families who are making decisions
about whether or not we will actually donate. So that women who act as
surrogate decision makers for patients who are brain dead in hospitals,
donate more frequently than men when they're asked. The families
of younger patients donate at higher rates than the families of older
patients.
So we know that consent for pediatric donors is considerably higher
than that for adult donors and as the age of the potential donor
rises, the consent rate falls. And individuals who discuss donation
with their families are more likely to become donors. So looking
at these factors, what does the public really know about organ donation?
The interesting thing is that because most people are going to be
brain dead when they donate, one of the critical factors has been,
well, what do people understand about brain death. And one of the
things that we found out in doing a variety of surveys is that less
than half of the general public understands that patients are on
respirators when the organs are removed, therefore, most of the
public does not understand the process of organ donation. Most
people think they take the patient off of support when they obtain
organs and we know from research with families who actually donated
that this is also the case. Not just the general public, families
who actually donated also have these misconceptions.
Over a quarter of respondents believe that brain dead
people can hear, for example. And about half —and I think that
reflects the fact that about half of the general public believes that
people who are brain dead are not quite dead. So when we talk to
people what they say is, "Well, they're not really alive the
way I'm alive right now but they're really not quite dead,
they're somewhere in the middle." And many Americans are
concerned that organ donation results in the mutilation of the body.
And this is a particularly interesting and significant belief because
we are the only developed country in the western world that currently
practices open casket funerals by a majority of the public so this is
clearly a real concern for people.
Over a quarter of Americans believe that if doctors know
they're willing to donate organs, they wouldn't do as much to
save their lives. Three-quarters of Americans believe that rich and
famous people are more likely to obtain a transplant, and most
Americans believe, though, that patients will be correctly diagnosed as
dead when the time comes. So there's a certain amount of
mistrust. There's a bit of mistrust about, if I actually designate
myself on my driver's license as a donor, will they just look at me
and say, "Oh, they're a donor, let them die, we'll take
their organs."
And minority communities in particular are very mistrustful
of this issue. And the other thing is that there's issues around a
belief in the equity of the system, so that three-quarters of
Americans, including when we do this with health care providers,
believe that if you're rich or if you're famous, you really are
more likely to be transplanted than you or I.
Now, in terms of people's prior behaviors about organ donation,
as I mentioned, we know that about 40 percent of Americans have
signed a donor card or signify that they're donors on their
driver's license. And about half of Americans have actually
their families that they want to donate and again, these particular
behaviors are very important. They're very important because
when people know that somebody is a donor, wants to be a donor,
they're far more likely to donate. In fact, we've passed
in this country a number across, I think about two-thirds of the
states, laws called first person consent in which those signifiers
on your drivers' licenses are binding. In other words, you
don't have to ask that family any more whether or not they would
be willing to donate.
And I think this is actually a good thing because one of
the things that — one of the reasons that we passed this legislation
is that people had a misperception that families countermanded
patients' wishes and this is actually an example of what had been
a successful policy being passed for the wrong reason. In point of
fact, very few families ever do that, but what they do do is they
really want to know what their family members want and when they
don't know, they tend to err on the side of caution, which is
non-donation rather than donation.
The second component which may be less interesting to you,
but I thought you should be aware of, is what happens between hospitals
and organ procurement organizations. This is a very important
component to organ donation because remember, people are brought into
the hospital, mostly — 99 percent of potential donors are located in
the intensive care unit. Somebody has to recognize that that patient
is potentially a donor and the current regulations stipulate that then
the OPO needs to be called by the hospital and the OPO needs to come
out and make an assessment and is responsible for making a request to
the families of the patient. So obviously, if the hospitals don't
do their part, there are no calls to the OPO. Therefore, there is no
organ donation.
So you can't ask family if nobody knows they're
eligible and what we've seen in our studies is that hospitals, at
least level 1 trauma centers where most of these donors are located,
are reasonably good at it and between 70 and 100 percent in our studies
actually will correctly identify potential donors. However, the next
step is that somebody needs to call the OPO on a timely basis.
It's not enough to call the OPO after the patient has been removed
from supports and that happens quite frequently, where they'll call
and say we have a potential donor, however, the family has left the
hospital. However, the family has already decided to remove the
patient from life support, or we already have, too.
So you may be at the letter of the law, because the law
doesn't stipulate, but you're certainly not complying with the
spirit of the law because if you don't refer in this way, again,
the family doesn't have the opportunity to consider this. Now, we
could consider this from a purely utilitarian thing, which is that, you
know, we want people to recognize donors because we have a utilitarian
purpose for it, but we could also consider it from a consent issue,
which is that this should be something that all families have an
opportunity and a right to consider. They have a right to refuse but
they should have a right to consider it if it's pertinent. So what
we've found is that timely referrals are even more variable than
identification and there are actually some hospitals that never refer
on a timely basis and some hospitals are very, very good and about 90
percent of the time they will refer on a timely basis.
Now, the last component, and in some ways what may be the
most important component, is what happens during the request process.
In other words, who asks the family, when do they ask, how do they ask,
how much time is asked and I group that under the rubric of what I call
effective communication and I've given you a definition of
effective communication which is truly essential for obtaining
consent. It entails discussing the option to donate with families in a
way that provides them with sufficient information to make an informed
decision within an environment that maximizes their ability to consider
the request. Requests can be persuasive but not coercive. And of
course, I'll leave you all to debate that issue. I'm not going
to do it myself.
So what happens during the process? Well, again, we're
looking at critically ill patients, patients who are terminally ill.
They're on complete life support. Their brains are either ceasing
to function or no longer functioning. So clearly, there's a lot of
things that have to happen and one of them is preparing the family for
the patient's inevitable death and also trying to make a donation
request while that all is occurring. What I want to talk about and
sort of point out to you is the things that can happen during that
process that make it more or less likely that families will donate.
Families are more likely to donate when they understand
that the patient's condition is hopeless. They're more likely
to donate when the possibility of donation is raised once the likely
terminal nature of the patient's condition is known, not after
they've declared the patient dead, brain dead, not after the family
has decided that they want to remove life support but before that, once
they know that the condition is futile.
Now, the interesting thing is that I believe the family
should all have a good explanation of brain death for them. However,
what you should know is that understanding brain death is not
associated with consent to donation. In fact, in our studies of
families who've considered requests for organ donation, what we
found was that more than half of those families really did not
understand the concept of brain death, didn't really understand
whether the patient's organs were taken before or after they had
technically died, and were more likely to donate when they said that
they were unclear when the patient had died. And I can discuss that
further, I see some people's knitted brows about this, but those
are the results.
And again, people make their own judgments about life and
death. They often don't use our medical concepts of death. We
often would hear families say things like, "I know that they said
they were dead at this time, but the minute I saw them in the hospital,
I knew they were gone." For them, that's when the patient
died. The other thing is that we talk about the use of relational
communication techniques to make those requests and these are the sort
of things that always should happen in healthcare settings with
families of patients, whereas you have to build rapport with the family
and the family's values and the patient's preferences
concerning organ donation have to be solicited and actively listened
to.
Certain types of information are very important to actually
making an informed decision, and this list is from empirical data,
where we know that understanding these issues makes a difference as to
whether somebody donates or not. So for example, it's very
important for families to understand and know what can happen in terms
of the funeral arrangements for the patient if they donate. They want
to know and need to know how the body is treated. They need to know
what the benefits of donation are. It's hard to make decisions
about things if you don't know what are the good things that could
happen because you donated and there's often an assumption that
everybody knows this but it's not, there's an assumption that
people that know that there's only about 12, 15,000 individuals in
the United States that die, are brain dead every year. They don't
know that. A lot of people believe that if they don't donate,
well, the person in the bed next to them can donate and that's
simply not true. So we need to give people real information for them
to make a really informed decision. They need to know that if they
choose to donate but they don't want to donate certain organs, that
they have the right. The need to know what the monetary cost will be
for them if they donate.
The need to have reputation of certain myths about
donation, such as that the body is mutilated as a result of donation
and we need to actively solicit again, the patient's wishes and if
it's a first person consent state, to check the donor registry.
The time spent with the family is very important and families need a
lot of time to consider this request; hence, again, it's really
important to ask earlier rather than later and they need to have
emotional support provided. So we know that the more time you spend
with the family, the more likely they are to donate.
We know that OPO staff have superior consent rates as
compared to other health care providers and you need to be trained to
do this. It shouldn't just be anybody doing this. And they have
to be provided with a comfortable environment, again, providing them
time and emotional support. I thought you might be interested to see
why people decide to donate and why they don't donate. What we
found from real families who made these decisions is that for people
who donated, 78 percent donated because they felt that it would help
other people, 75 percent because the patient communicated a wish to
donate, 62 percent because they were just kind of generally
pro-donation, 32 percent because it would help them cope with the loss
of the patient and 22 percent because they felt the patient was gone
and they didn't need the organs anyway.
I want to point something out about this list, which is
that it's not a linear list. Everybody who donated had at least
two reasons, mostly three reasons for why they donated and actually,
although altruism beat out patient communication, a little, and I'm
not bringing the really complicated analysis we did on this, what you
should know is that the two reasons that were actually more important
than altruism was knowing the patient's wishes, again, acting as a
good surrogate and being generally pro-donation.
Now, why do people refuse? And here the interesting thing
is that many people actually had a single reason for not donating, and
they were much less complicated about why they didn't donate than
why they did. And again, this whole issue about being the good
surrogate, 51 percent didn't donate because they thought the
patient wouldn't have wanted to donate. Now, sometimes that's
because they had an explicit conversation. Other times, they were
casting back and just thinking about everything they knew about the
patient to come to that decision. Forty-four percent was something
that we call family stamina. The family just didn't have enough
emotional energy to go through the donation process. They had had
enough. They felt they had been through enough and they just
didn't want to go forward with it any more. And again, I think it
speaks to the issue of providing the family with a real environment
where they can actually do this.
Forty-three percent had disfigurement concerns, a quarter
mistrusted the health care system, 19 percent thought the patient was
ineligible. They were incorrect in that judgment, but they made that
judgment themselves and in 14 percent of cases there was disagreement
amongst family members. So technically there is a legal next of kin
that can make those decisions, but frequently these are family
decisions and most family members will not override other family
members, so if a son wants to donate but his other siblings do not, it
usually means that they don't donate.
The last — so those are essentially, I think the real
issues around organ donation. That's really a summary of what we
really know about why people do or don't donate and the components
that are important to donation. The last two things I wanted to talk
about were organ donation in minorities and policy issues.
As you probably all know, minority groups have a pressing
need for transplantable organs, particularly kidneys, and just to show
you a little poll data, probably the best data we have that compares
three different ethnic groups, we know that this one poll said that 87
percent of whites expressed support for organ donation, compared to 69
percent for African Americans and 75 percent for Hispanics. Donation
rates, as I mentioned, are half that of whites and minorities are also
less likely to have made a decision of organ donation for themselves
and they're less likely to have communicated that decision to a
family member. All those things mean that when we look at this, we
should see lower donor rates, and, indeed, we do.
Why doesn't the African American community donate, and
I'm going to concentrate on the African American community, because
it's the community we know the most about. They're the most
studied and it's also the community that has an incredible need for
kidney donation. Despite a lot of work, there is still a lack of
knowledge about the need for organs in the African American community.
There's also a mistrust of the health care system. When you look
at that quarter of people that say they mistrust the health care system
and they didn't donate or don't want to donate because of that,
if we look at those numbers for African Americans, it looks more like
40 percent for African Americans, and it's not just around
transplantation, it's around the health care system in general.
And then what we know is that African Americans experience
different donation requests than white families and I'll just go
into that a little more. What we know happens in the hospital with
African American versus white donors is that if you're African
American or a member of an ethnic minority, you are actually less
likely to be identified by the health care team as a technically
eligible donor. You are less likely to be asked as a family about
organ donation if you are an African American family and in another
study what we found was when we asked health care providers to assess
whether or not families were pro, wanted to donate, didn't want to
donate, or were undecided, they were markedly more likely to
misconstrue the intentions of African American families as not wanting
to donate even when they did want to donate. So, again, I think
there's a lot of stereotyping going on.
And then finally, I wanted just to talk a little bit about policy,
and of course, I don't have to tell all of you the procurement
system is voluntary and it relies on the public to give gifts to
a publicly regulated and funded system for organ donation and the
system has only sort of minimal oversight for tissue donation.
I think there's an assumption, is that we can all be asked to
donate for the public good and there's a community based organization,
those organ procurement organizations, that are responsible for
procurement. I think some of the issues that need to be considered
are that there are significant numbers of people who actually donate
in this country, who if they themselves needed an organ could not
receive one because of financial issues. So that we do have a system
that's publicly funded. We do want everybody to donate for
the common good but not — everybody can give but not everybody
can receive.
Over the years, there's been all sorts of policy and legislative
approaches and usually I start most of my talks with noting the
number of people on the waiting list. There's currently about
93,000 people on the waiting list at UNOS. When I first started
working in this area in the 1980s, there were 25,000 people on the
waiting list, it was considered a crisis. As a result, we passed
required request laws that said that the hospital is responsible
to make sure that they asked all the families of donor eligible
patients. Those laws did not really result in the increase in donation
that we had hoped.
The next set of legislative responses was routine
notification which is our current system. It basically says that the
hospitals need to call the OPO who need to come in and request organ
donation. That has bumped up the rates of notification and
identification so that we've been able to get more organs but the
actual consent rates are still the same, they're about 50 percent.
There have been some hospitals that belong to something called the
collaborative that have done much better but still, overall the rates
are a little better but they're not great.
The next thing has been state initiatives for first person
consent where we have binding registries. Those registries are great
as long as when we request those, people are given complete options
about what they want to donate. So for example, in the state that I
live in, in Ohio, you just have a blanket check and a lot of people
don't realize that that includes tissues as well. A lot of people
never thought about that, so that could be a problem in registries.
There have been suggestions for mandated choice, that everybody
is required in this country to choose. They tried that in the State
of Texas. It didn't work very well. Everybody just opted out.
Presumed consent, which is a European system, which presumes that
everybody wants to donate unless they actively opt out. They tried
to pass that in Pennsylvania in the 1990s. That failed legislatively
and as I will show you, it doesn't have a lot of public support
and then financial incentives which the Institute of Medicine dealt
with recently.
And just a last slide and I'm done, just to give you an
idea, most Americans do not favor presumed consent laws. The majority
of Americans are against those types of laws. They think they go
against people's sense of autonomy and again, there's fears and
mistrust about the health care system. The overwhelming majority of
Americans though did agree with first person consent laws so
they're comfortable with those laws as long as you can document
that somebody really does want to donate. Half of the Americans
believe that it's acceptable to provide donor families with money
for funeral expenses and many more African Americans than whites favor
such a policy, which is interesting.
And only a third of Americans don't favor any other
type of financial incentive. So in terms of financial incentives,
funeral benefits actually is an acceptable financial incentive for most
Americans. Anything else is not proven to be. And then lastly, less
than half of Americans believe that donors should be able to designate
a recipient. Most Americans are uncomfortable with that idea, that you
should be able to say, "Well, I want to give my relatives organs
to this person rather than this person or this type of person rather
than that type of person." So, thank you very much. I'm sure
you'll have some questions and I believe my time is up, thank you
again.
(Applause)
CHAIRMAN PELLEGRINO: Thank you very much, Dr.
Siminoff for this fine overview of the socio, cultural and ethnic
dimensions of the process and the perspectives on organ donation. Next
we will hear from Dr. Neil Powe —
DR. POWE: Powe.
CHAIRMAN PELLEGRINO: Powe, thank you very much,
Professor of Medicine and Epidemiology and Director of the Welch Center
for Prevention, Epidemiology and Clinical Research, Johns Hopkins
University Bloomberg, School of Public Health. Following Dr.
Powe's presentation, we will open up the discussion.
DR. POWE: Well, I want to thank you for the
privilege to come before you today to talk about a subject that's
near and dear to my heart. I was asked to come to address the need for
organs, whether there actually, truly is a crisis in this country or
even in the world in relation to the need for organs. So that's
what I intend to do. I'm sure you've seen statistics like
this. And I am going to show some slides today. I cannot ever do a
presentation without data. I live in data every day, but I hope
it's not too — these statistics are not too troublesome.
This shows the number of people on the wait list. As Dr.
Siminoff has said, there's about 90,000 people now on the waiting
list but only 26,000 transplants and 14,000 donors in the country. And
you can see there's a widening gap over time. So what I'm
going to talk about is the growing prevalence of chronic disease.
I'm going to talk about kidney failure, an area that I've
worked in a lot and a little about heart failure; the prevalence and
incidents, the causal — something about the causal factors driving
this, treatment and prognosis, quality of life and cost, and show you
data by different transplants of the waiting list and then summarize
this.
So chronic disease is a disease that lasts a long time. Chronic diseases
are unlikely to be cured in the near future. Progression can lead
to organ failure, that is what we often refer to as end stage disease.
And this is true in conditions like diabetes, hypertension, heart
disease and kidney disease. You can see there are about 58 million
total deaths in the world each year. And it's believed that
35 million people die from chronic disease. That's 60 percent
of all these deaths. And that chronic disease accounts for about
75 percent of health care spending and, in fact, that's due
to increase even more because of the older — the aging of
the population.
And some chronic diseases and their antecedents are
increasing, so you all know that obesity is increasing. Obesity, then,
is a determinant in the increase in diabetes and diabetes is a
principal cause of chronic kidney disease. So when many look at the
causes of chronic disease, they are multi-factorial. They include
underlying socio-economic, cultural and political and environmental
determinants, and then common modifiable risk factors such as health
behaviors, other healthy diets, physical activity, tobacco use, and the
non-modifiable risk factors, age and genetics. They also include
intermediate risk factors, such as blood pressure — rise in blood
pressure, blood glucose, abnormal blood lipids, and then overweight and
obesity as I mentioned and these are determinants in many of the
chronic diseases that we see today.
But we don't know what those — how those determinants
interact or even how to best intervene. This shows again, data on —
current data on the number of transplants and waiting lists. You can
see the kidneys are far the group that is one of the largest in terms
of transplants and in terms of the waiting list and then followed by
liver and then smaller numbers for pancreas, heart and lung.
So let me talk about kidney disease, an area that I've
worked in the last 15 to 20 years in my career at Johns Hopkins. And
there's a huge public health burden in chronic kidney disease.
There's over 400,000 people in this country are treated for end
stage renal disease and the cost of that treatment is about $50,000.00
per patient per year, an aggregate cost to the Medicare program of $17
billion a year. And you can see this graph that I've put together
for you that shows in 1972, our Congress decided to pay under the
Medicare program for patients to receive dialysis or transplantation
for end stage renal disease, probably the only disease in the history
of our country that was paid for particularly on a disease specific
basis and there were about 17,000 patients in the first year of the
program and that's now grown, as I said, to 400,000 patients. And
you can see this is a growing chart and the cost associated also
growing.
Well, this 400,000, this is a little old slide, it was
300,000 when I did this a couple years ago, is fuel. It's only the
tip of the iceberg because recently we've been able to show in the
population by one of my colleagues, Joe Korsch, that there's a
large number of patients who are in earlier stages of kidney diseases,
about 8 million individuals in this country who have what we call Stage
3 chronic kidney disease and this is marked by something that we call
glomerular filtration rate which we measure through blood
measurements. So this is something that we haven't seen yet and
probably what's fueling this 300 or 400,000 patients who have end
stage disease. And so when people try to project this out, this is
what we end up with. By 2010, it's thought that there will be
about 600,000 patients in this country. This has been a two-fold
increase of prevalence over just a decade and it continues to rise.
Well, what's the reason for this, well, the aging of the population
as I mentioned. Kidney disease is associated with age. The most
common cause of kidney disease is diabetes and we know diabetes
is fueled by obesity, another epidemic in our country. And as
Dr. Siminoff said, the racial characteristics of who gets these
diseases is also staggering. African Americans are about somewhere
between three to seven times more likely to develop chronic kidney
disease. What's less certain is whether there's been improved
survival of individuals treated by therapies like dialysis and transplantation
or whether, in fact, we're seeing people with kidney disease
because we're saving them from other diseases like heart disease,
cardiovascular disease treatment. Some of my colleagues and I have
tried to tease that out but it's very difficult. This shows
the epidemic in the minority community. African Americans have
a much higher incidence than whites and also Native Americans because
of high rates of diabetes in Native Americans. That's also
true that Hispanics have a large degree of ESRD.
Some of my colleagues and I, we've tried to explain why there
is this excess risk of chronic kidney disease in African Americans.
I think it offers some illustrations of the causal factors that
may be at play. This slide shows the relative risk of blacks versus
whites, greater than — Blacks are almost two to three times
more likely to develop end stage renal disease. What we control
— that's controlling for age and sex. If you control
for socio-economic status you can explain 12 percent of the excess
risk. If you control for lifestyle, about 23 percent of the excess
risk and if you control for the care they receive, medical care
they receive, about 32 percent of the excess risk. But all these
factors together, you can explain almost 50 percent of the excess
risk. That's good news because lifestyle and care quality we
can do something about but there's still 50 percent of the excess
risk that we don't have a clue as to why. And so more work
needs to be done to understand that.
Well, what is it like to have end stage renal disease?
These are some pictures. There's two ways to treat this. One is
dialysis and one is transplantation. If you get hematolysis, this is
what you get. You spend 12 hours of your week, four — three times a
week visiting a dialysis facility, tethered to a dialysis machine. You
can sit, watch TV, read but you're there for 12 hours for the rest
of — 12 hours a week for the rest of your life. Some patients choose
peritoneal dialysis where they — instead of getting their blood
filtered — the impurities filtered from their blood, they do it
through their abdomen and they do it at home on their own, and hooking
a bag of solution that goes into their abdomen and then we drain that
out by gravity.
Some patients do it at night using a machine that actually
cycles the fluid into the belly and out. I've studied a lot of the
quality of life and mortality of different types of dialysis and there
are differences but the main difference is that if you're lucky to
get a transplant, you're much more likely to live, 80 percent
survival over five years versus if you're on dialysis less than 50
percent of patients who undergo dialysis are alive in five years. So
really getting a transplant makes a difference. And the risk
is not — it's different over time. There's a higher risk of
death in the early stages of transplant. There's the risk of the
operation but over time, the risks of death go down.
What's quality of life like? Well, we've studied
chronic kidney disease in patients, asking them about their quality of
life. And it turns out on average, about 30 percent — on average,
they're willing to sacrifice 30 percent of their remaining life
expectancy for good health. So they're willing to trade off some
time for an improved quality of life, a significant amount of time.
They also had many other comorbid diseases and complications which go
with kidney disease, meaning they're hospitalized about two times
per year and they take on an average seven to 14 different medications
a day. This also shows what it is in expenditures comparing dialysis
to transplantation and actually transplantation here is cadaveric and
living related transplantation costs more in the early part due to the
operation but over time — this is the dialysis cost, about $50,000.00
per year, but over time, you can see that actually transplantation is
less expensive in the long run than dialysis.
And so this is — this epidemic of kidney disease is why we
have this disparity of people waiting on the waiting list, 60,000
patients waiting for a kidney and only 15,000 transplants being
available, most patients, as I said, being relegated to dialysis.
Let me say a little bit about heart failure. Heart failure
statistics are very hard to come by. Part of the reason is that
because Medicare has paid for kidney disease in this country, we have
very good statistics on who gets — who has the end stage disease.
It's not as true for heart failure, but this is what people have
been able to glean and put together. There's about five million
people with heart failure in the country. That's heart failure of
any severity, about a half a million people who develop it each year,
57,000 patients who die each year. It accounts for about a million
hospital discharges. In fact, it's the number one reason in the
Medicare population for hospital discharges at a cost of about $30
billion to our country.
The prevalence of heart failure varies by age, about 10
percent in those over age 70 compared to two percent if you're less
than age 60. And the determinants of heart failure are largely those
who have ischemic heart disease or coronary heart disease, accounting
for about 70 percent of cases of heart failure. In fact, most people
believe what fuels this is that we've developed very good
therapies, kind of half-way technologies for treating heart disease,
revascularization therapy, whether that's thrombolytic therapy,
clot busting drugs, or coronary artery bypass graft surgery or stents,
that actually save people's lives but they actually leave the heart
muscle still damaged and so that leads then to progressive heart
failure. And because of that, we can keep people alive but patients
are going to go on to develop heart failure. In fact, we see deaths
from heart failure increase over the last few decades.
The prognosis for heart failure can be poor. It's a
progressive disease. Yearly survival depends on what class of heart
failure, kind of stages of heart failure that we use. If you're in
a mild class, it's — the yearly survival is about 85 to 90
percent, but it goes down to 50 to 70 percent if you're a Class 4
and this is about a quarter of patients. Those patients that have
refractory symptoms at rest meaning they're short of breath at
rest, they would be candidates most likely for transplant, have a 50
percent survival of just six months. So their survival is really
poor. And as I mentioned, it's the number one reason for hospital
admissions in the Medicare program.
How do we treat heart failure? We can treat through
medications, a lot of emphasis in the last few years on disease
management, education, case management, prevention efforts, exercise
training and then our technology. Implantable defibrilators are now,
biventricular pacing is shown to give hearts a boost in their pump
function. And then mechanical support devices mostly now used as a
bridge to transplantation but not in and of themselves long-term
therapy. And then transplantation, which has been really reserved for
less than five percent of those with advanced heart failure get
transplantation but I expect this actually will grow.
This is what the heart waiting list looks like. We're
seeing a little decline in the waiting list, probably because we're
getting a little bit better at the eligibility characteristics for
those who are eligible for transplantation. Patients with heart
failure at least Class 4 heart failure, have a miserable life. If you
ask that same question I said to dialysis patients, those with end
stage renal disease, the Class 4 heart failure patients are willing to
sacrifice about 70 percent of their remaining life expectancy to have
perfect health, trade that amount of time off.
So back to this slide, this 90,000 people on the waiting list,
I think it's real. I think there is a crisis of chronic disease
an end stage disease in this country fueled by a variety of factors
that we don't understand and they're increasing. We, as
well as others, are trying to understand why this is. I think preventive
efforts are extremely important but they're unlikely to immediately
address the loss of life and suffering by several hundred thousands
of persons each year and as Dr. Siminoff said, the problem is particularly
important for some disadvantaged groups in this country.
So I think this is real, I think it is a crisis and I think
we need to do something about it.
(Applause)
CHAIRMAN PELLEGRINO: Thank you very much, Dr. Powe, for your
very, very concise summarization of the very critical clinical data
that must figure in any consideration of an organ donation program
as well as the data we heard from Dr. Siminoff. I'm going to
ask one of the members of our Council, Dr. Daniel Foster, to open
the discussion of both these papers and then all the rest of the
council members, we hope will contribute their observations and
questions. Dr. Foster.
DR. FOSTER: Well, I'm sure I speak for the
Council in appreciation for both presentations. Let me begin with the
first presentation to ask a question in what might be called a reality
response to the summary of all the things that lead to and lead away
from donations and that question has to do with the issue of time.
Almost everything that you said focused in terms of preparation for
time, we have to start early if we think that there might be an illness
that would lead to a donor. We have to spend much time with the family
at the time of the event and one of the absolute realties that all
physicians deal with now is the lack of time because of payments and
all sorts of things that — follow-up visits in the office which might
have been 15 minutes are now five minutes. It's standard
for a new patient work-up in internal medicine which for years was an
hour is down to 30 minutes or 15 minutes or less. So hovering over
everything that you have talked about is the pressure of time. Most
physicians, even really caring physicians, are not going to be able to
spend an hour or two hours with a family regarding donation. I mean,
it might take — I'm actually involved in one myself right now.
There's just not time to go over all of these issues, to talk to
the siblings, to do all of those things.
Another matter of time is that many of the deaths come
quickly, if it's trauma, you're riding a motorcycle without a
helmet and so forth, and so there's a time element which is
involved there. And finally, there is the issue that most of the time
the trust is involved if there is an ongoing relationship with the
physician, for the physician to be there, but in most hospitals, death,
even — certainly random deaths come with the physician of record not
being there at all, so it's going to be a resident or something of
that sort.
So I think that what I'd like to open the discussion
with is your response to how do you think that we're going to have
time and resources to do all these things, not to mention the proposals
which we'll talk about later, the IOM report and so forth, for
starting education very early in life and so forth. I wonder if you
would just comment on that reality factor.
DR. SIMINOFF: Yeah, and I agree with you and I
think one of the reasons in our studies physicians have the worst
consent rates of any health care professional is because they do not
have the time to sit with the family and do what really needs to be
done. Required request laws failed because they gave that
responsibility essentially to the hospitals and to the physicians to
do. The current regulations, however, don't really stipulate that
the physicians or even the hospital staff have to have that
responsibility.
Currently, what is supposed to happen is that somebody from
the hospital needs to tell the organ procurement organization that
there is a potential donor. It then becomes the responsibility of the
OPO to do that, to spend the time with the family. So really what
really needs to happen and the most successful hospitals, the most
successful models of this are when the health care providers call
early, the organ procurement organization staff that's trained to
do this comes early. The health care providers are then responsible
for making the introduction. They do not have to stay for the entire
thing, In fact, mostly they do not and then they leave and the OPO
staff are then the people that will spend the hour, the two hours,
sometimes the 12 hours with this family. Otherwise, you're
absolutely correct, there's no way physicians could do this, and
they weren't doing it and they weren't able to do it.
And so now really, what I think needs to happen in
hospitals and particularly for a lot of intensivists who care for their
patients, they really need to start becoming comfortable with doing
this, with saying, "We really can't do this, it's just
impossible for us. We need to give this responsibility to somebody
else understanding that we have hopefully a good relationship with
these people," and that was sort of the second element of
developing that relationship of trust between the hospital and the OPO
and then feeling that when I introduce this staff — this OPO staff
person to the family, I can feel confident that they will treat this
family with respect and with sensitivity and that they will do a good
job. So that is really where things are going and I think need to go
given the constraints.
And again, when you mentioned sometimes things happen very
quickly medically with these patients, again, that's the other
reason why it's very important for the OPO to be called quickly.
Now, there are some different models. For example, in some very, very
large level 1 hospitals they've put in what they call in-hospital
coordinators. These are people from the OPO and their job is to be in
that hospital 24/7 and that's what they do. So basically, the OPO
always has somebody on call at that hospital.
Now, as a model, that works very well in extremely busy
trauma centers. It's not a financially feasible thing to do in
level 1 trauma centers that have maybe some donors a year but not on a
regular basis, then we're back to the calling early thing.
DR. FOSTER: Well, the teaching hospital that I work
in, in Dallas takes care of the poor and largely minorities and so —
and the people that — the OPO people that come are actually very good
and so forth. Nevertheless, often times if it's a patient
that's under the physician's care, they in responding to that
kind still say, "I want to talk to my doctor, you know, to do
that." So that it's pretty hard to eliminate that. Also, I
didn't mention the fact that, of course, in most major hospitals
now, hospitalists are there and many of the internists and, you know,
family practitioner has turned it over to a strange doctor who is
there, which makes it a difficult thing. But I think your answer is
probably the best way we can go as to have that sort of training and to
— and big trauma centers, which we are, to have a full time group
which would be present. So I think that's something we're
really going to have to think about and the cost.
I don't want to dominate things, but I want to ask Dr.
Powe one question about his presentation then we'll throw it open.
The issue of the increasing number of patients with end stage renal
disease and as you point out, almost all of them do die of heart
disease, they've all got endothelial dysfunction. I mean,
we're going to have to figure out what's going on with that.
The estimates of how many physicians one needs in the country vary.
You know, we go through these cycles, well, we have too many physicians
and therefore, we have to stop training programs and now the estimate
is, well, there's going to be a great shortage of physicians. Our
own State of Texas has mandated that the medical school increase their
entering classes much to my distress, 20 percent to increase the
residencies and so forth, just to increase the doctors in Texas.
We're coming to a time where the nephrologists are
reaching retirement age, the people who have gone — you know, when you
first started this specialty and so forth, and so there is also, I
believe, a considerable concern about having enough nephrologists to
deal with this massive increase in renal failure, which, like you, I
think will continue to increase. I wonder if you would comment about,
not the need of an organ which we're going to discuss, but the need
for somebody to care for all these persons who live longer and
they're more sick and go into the hospitals much more frequently if
they're on dialysis than those who have had a transplant.
DR. POWE: I think actually, it's not really the
patients who have end stage disease. I believe actually the numbers —
there have been, actually a person power estimates or workforce
estimates for nephrologists but I'm a primary care physician, a
general internist, and it's true that there probably are enough
nephrologists in the projections to take care of patients with end
stage disease. The problem comes more of those 8 million that are
under the iceberg. And if all those were to land in nephrologists'
office, nephrologists would be overwhelmed so they couldn't take
care of the sicker patients.
And so I've actually been doing a lot of work in
educating primary care physicians about patients with less degree of
renal function in managing where now we are beginning to have drug
therapy that can slow the progression of disease, can't eliminate
it but slow the progression, things like ACE inhibitors and ARBs when
patients are properly chosen for those therapies. So that's where
I think the workforce issues are and probably even more acute for
primary care physicians since less people are going into primary care
at this time.
DR. FOSTER: Well, just personal experience, I
don't have national data on this but at least in Dallas we often
times are having to keep patients in the hospital on dialysis because
there's no slot for chronic dialysis and if you're a
nephrologist in Dallas, I mean, every group is looking for additional
people and having some difficultly in finding them. Maybe they
don't want to live in Dallas. After all the Mavericks lost, but I
mean, I do think that there may be even apart from the internists and
family practitioners who take care of the earlier stages, that this may
be a potentially difficult problem because I don't believe that the
renal — I could be wrong about this and maybe Dr. Hippen will want to
talk about that, but I don't believe that the number of slots for
nephrology training programs are actually increasing and it seems to me
that that might be a problem.
DR. POWE: They're maintaining but then it's
what nephrologists do. If they were to shift more to taking care of
the end stage patients more and that was their major role versus the
earlier patients, so I think that's the issue of where they work.
I don't want to give the impression — the availability of dialysis
is wonderful today. Most of the units in 1990 were in-patient units
but by the end of the early 1990s most of the units are outpatient. So
most of the units are not even affiliated with hospitals but
free-standing dialysis units in the community and they have doubled to
tripled over the last couple of decades so the availability of dialysis
treatment is very good in community centers, often started by now
for-profit dialysis facilities. It's become a for-profit business
in this country. About 80 percent of patients are taken care of
for-profit facilities, so the capital to build dialysis buildings and
facilities has been there through this for-profit market.
CHAIRMAN PELLEGRINO: Other questions, comments?
Please.
PROF. SCHAUB: Yeah, I have a question for Dr.
Siminoff. Has there been a generational shift in the willingness to
donate? I mean, are young people more likely to check the driver's
license box than older generations?
DR. SIMINOFF: I don't think we have good data
on that, so I really can't answer your question definitively. What
I do know is that when we speak to potential donor families, that as I
said, the families of younger patients do tend to donate more
frequently. And those family members tend to be younger. They are
usually making decisions about young adults or pediatric patients.
They, themselves, are younger and they do tend to have more positive
views and they've heard about it and they discussed it in school.
So my guess would be if somebody actually did the study and looked at
the data, that there is somewhat of a generational shift in this and
there has been a consistent rise so that about 20 years ago, I
don't think any more than 20 percent of the population had checked
something off on their license and that number has doubled. So there
definitely has been an educational shift in the country as people
become increasingly aware about this issue.
PROFESSOR SCHAUB: Do families themselves ever
initiate the process? You mentioned sometimes —
DR.
SIMINOFF: Absolutely they do.
PROFESSOR SCHAUB: — in hospitals —
DR. SIMINOFF: About a quarter of donor families
actually initiate it themselves.
CHAIRMAN PELLEGRINO: Dr. Rowley?
DR. ROWLEY: I have two questions for Dr. Siminoff.
The first question has to do with that data that we got that I think is
not from you that indicated that individuals over 65 are now donating
organs where they didn't used to or another way of putting that is
that transplant services are realizing that older donors may be of
value. The question is, is there any data available on say the
survival of individuals transplanted with organs taken from older
individuals as compared with younger.
And so the question — there are two questions, one of
which is related to the enormous increase, more than three times, in
the period for which we were given data in use of older individuals as
donors and the second is the viability of organs taken from older
individuals.
DR. SIMINOFF: I'm going to somewhat answer your
question and then I may punt to Dr. Powe about the medical aspects.
What you're talking about is the expanded donor criteria. And so
that is not so much a consent issue as it just is a willingness on the
part of transplant surgeons now to accept donations from people who are
older. And the interesting thing, I think I showed you is that about
19 percent of families deny donation because they don't believe
that their relative was eligible. Those tend to be the families of
these older donors who, when you talked to them say, "I know they
asked me but they were mistaken. They don't understand, you know,
my dad was a smoker or my uncle drank a lot and nobody would really
want their organs, they're too old."
So we do need to educate the public at this point that
donors are not simply 20-year old men who ride motorcycles without a
helmet like in Pittsburgh. They are many, many other people. I
believe that those organs are viable although I'm not sure they do
as well and I think there's been discussion about whether we really
should be talking about if we are going to be taking organs from this
expanded donor pool, would it be better to preferentially transplant
those organs into older recipients, but maybe Dr. Powe has some
thoughts about that.
DR. POWE: Yeah, there's been a lot of work on
what we call marginal donors or expanded criteria donors. Some of
those are donors that have high blood pressure, that have been obese,
that might actually even for themselves, if they give a kidney, have to
worry about their own health in the future, and then whether the
actual, you know, kidney will survive. So the premise with this is
that, yeah, with older age a kidney, renal function does deteriorate
over time so one, in fact, would think that a kidney from an older
recipient may on average not do better than someone from a younger
recipient. That's probably true. But because we look at the
kidney function, you know, and look at eligibility, you know, not every
older person is the same in terms of the disease that they have, so
that has to be looked at and that's what surgeons do and transplant
nephrologists do when the select someone for an organ.
The other thing is that this is a moving target because
immuno-suppressive therapy has gotten so much better over the last
decade that, in fact, the rejection of organs has gone down and
we're getting better and better at that. So we're extending
the life of organs at the same time.
CHAIRMAN PELLEGRINO: Dr. Kass.
DR. KASS: Thank you. This is a question for Dr.
Powe. And it goes to your sort of projections of what's in store
for us even as early as 2010 in terms of the growing number of people
with end stage renal disease and presumably, the growing, therefore,
number of people on the waiting list unless there is some kind of
radical solution to the so-called transplant shortage. It seems to me
that if these numbers are right, we are, in fact, facing this
shortfall, the shortfall that we face now is nothing compared to what
we are likely to see going forward.
And that raises for me
the question of whether it's right to begin to think of this in
terms of a crisis even now, because a crisis calls for really sort of
major and heroic kinds of interventions. Thirty percent AIDS incidents
in the male population in sub-Saharan Africa, that's a crisis for a
community. The fact that the mortality rate in the United States is
exactly 100 percent is not a crisis. All of us are going to die of
something and I notice from the figures that we were given that on the
waiting list already, 60 percent of the people on the waiting list for
all organs are over age 50 and 14 percent of them are over age 65. A
sixth of the people on the waiting list for kidneys are 65 and older.
If we manage some of these other symptoms, lots more old
people are going to be transplant eligible as the only way to avoid a
demise. So I guess I would invite you to tell me why you think this is
a crisis and a crisis for whom. It's sad, I don't deny that,
but if we start talking about this in terms of a crisis and going
forward, nothing short of some kind of radical measures would somehow
meet that kind of need. And I wondered if — that was a bit
long-winded, I'm sorry, but I would like to sort of like to invite
your reflections, especially thinking ahead.
DR. POWE: Right. Well, this is a philosophical
issue. And, you know, as to — you know, when you speak to should all
— should those who are older be in the waiting list, have they lived
long enough? And I don't think our society has grappled with that
very well and is willing to refuse treatment especially for older
individuals that have the means to pay for that therapy. So I'm
not sure I can answer that question. This is a big issue for our
society. Other societies aren't in the position around the world
where they can offer marvelous and wonderful treatments to individuals
that we can in this country and so we're faced with this dilemma.
I mean, it used to be that in the advanced stage renal
disease industry people in Canada and the United Kingdom, if you were
over age 65, forget about getting dialysis, but now that's opened
up in other countries, too. Other countries are going to face this
issue in the future, too. I don't know how to solve it. It's
a rationing issue and an issue about how we deliver health care
politically, financially and philosophically.
CHAIRMAN PELLEGRINO: A small one.
DR. KASS: No, I appreciate the drift of the
conversation but one thing that is in your power is whether or not to
call this a crisis and since you used the term, I'd like to hear
you tell me why you want to call this a crisis especially if we
ain't seen nothing yet.
DR. POWE: I think it is a crisis. When I see, you know, organs
being sold over the Internet on E-bay, people desperate to get an
organ. Individuals that I know who have end stage renal disease
will do anything to get a transplant from their own family members,
too. That's something we really didn't talk about. I think
Dr. Siminoff's presentation was focused a lot on the cadaveric
group but also the living — related living, unrelated. At
Hopkins we're doing a lot of issues around people, if they're
not compatible swapping organs with others even if they're unrelated
to each other. These are the kind of things that are going on
today because the pressures of individuals who are — and more
individuals that are in this circumstance vying for this scarce
organ. So I think it is going to be a crisis.
It also depends on where you stand. You know, if you have
a family member that's effected by this or you're effected by
it, it is a crisis, there's no question about it. And the more of
us that are effected by it, I think the more it will be a crisis.
CHAIRMAN PELLEGRINO: Dr. Lawler? You're on the
list, Bill, I'm sorry. We have to remind you all that we have six
more to speak and we have a limited time. Peter?
PROFESSOR LAWLER: Let me get the elementary medical
facts down right. In this country we have millions and millions of
people who have kidney disease. Kidney disease is progressive. It
can't be stopped. It can be slowed down some basically through
blood pressure medications, but maybe not all that much in many cases.
So as we improve medical treatment, fend off heart disease and other
complications, more and more people are just going to live through this
thing and progress to end state or renal failure, right?
So this is the character of the time bomb that this is a
disease that many, many people have. As medical technology improves,
more and more people are just going to see it all the way through.
That is they're not going to die in the process, they're going
to die in the end of it, and is that really the nature of the crisis?
DR. POWE: Well, that's part of it. We really
don't actually understand that. And I tried to elude to that, part
of this is — in kidney disease is driven by the aging and we know that
age is associated with kidney disease. The number one cause, 50
percent of the cases of kidney disease, over 50 percent are due to
diabetes, okay. And we know there's an epidemic of obesity. So if
we could do something about the epidemic of obesity, we might, then
slow down diabetes, the whole pathway, but that's going to take
years. It's going to take years and I don't think we know how
to do that.
And then this other issue of technologies that we save
people's lives has been less proven although it certainly is a
plausible, you know, hypothesis. I actually believe that as we extend
life that's what we're going to be doing but the evidence for
it is not ironclad compared to where our efforts should be in terms of
other prevention efforts, for example.
CHAIRMAN PELLEGRINO: Dr. Meilaender?
PROFESSOR MEILAENDER: I have a question for each of
you. For Professor Siminoff, I just wondered with respect to these
first person request laws, you know, as it were a mandate that a
person's consent is simply overriding, I go into my license bureau
to renew my driver's license and they ask me, you know, what color
my hair is and I say, well, you know, (laughter) and they say, "Do
you want to be an organ donor," and I say, "Yes." In
what sense does that constitute consent? That's my question for
you.
For Dr. Powe, this may not be an answerable question, if
you want to just tell me that, that's okay, because —
DR. POWE: I'm used to those.
PROFESSOR MEILAENDER: — you deal with — you think
about sort of data we have about what has happened. But I just found
myself wondering, I don't know if there's any way for you to
think aloud about this question, if in 1972 Congress had not decided to
fund dialysis, what would our situation look like today? I'd just
like to hear you think about that if you're willing.
DR. SIMINOFF: I'll answer the simpler question
first. I agree with you that in terms of we — and again, I live in
the State of Ohio. I took my son to get his driver's permit and I
watched what went on and I was appalled. Now, he's thought about
this issue for years because of me but he's a somewhat unusual
16-year old. The real problem is, is that the driver's bureau is
not a very good place to make these decisions.
Presumably for most people they will have thought about
this and had other information. There certainly are pamphlets that are
given to people, whatever. That's why I eluded to the fact that we
need to make sure that we have registries that are; A, accessible to
people so that if they change their mind, they can easily do that, that
we have good, at least educational literature that gets handed out and
that people are able to see all the different things that they could
donate and are forced to tick them off one by one. That will make
people really think about what they're doing, you know.
And there are states that do this; they say organs, and they list,
hearts, livers, kidney, so you're forced to say to yourself,
"Do I want to donate my heart, do I want to donate my kidney,"
and then it lists all the tissue. That's why, for example,
it's not very good because it's just a very blanket sort
of thing. So I agree, I believe that most people need to give it
more thought than they would normally get in the bureau. I think
the presumption has been is that people have thought about it beforehand,
that this isn't really where they're consenting, per se. It's
where they're just designating their wishes from a prior thought
about it.
And there are many people that choose not to do this,
obviously. They either haven't thought about it so they're
uncomfortable checking, or they're uncomfortable checking it and
they really prefer to sort of say to their family, "If something
happens to me, I would like to donate so now you know." And
I'll let Dr. Powe project the future.
DR. POWE: Well, there actually is some evidence on
the issue. There was a researcher, Roger Evans, who did an interesting
study in the late 1970s and early 1980s and what he did is he looked at
the demographics of individuals who received dialysis for end stage
renal disease before the passage of the Medicare program and after the
passage of the Medicare program about five years later.
And what he found is that before passage, older
individuals, those that are unmarried, separated, or divorced, lower
income and minorities were much less likely to receive dialysis care or
transplantation. And then five years after the passage of the program,
the demographics, those disparities had actually decreased as a result
of the offering of health insurance. You could say this is much the
dilemma like the issue of the uninsured in this country today, but at
least from an equity issue, if that's important to you, that study
would probably tell us what the demographics would look like of
individuals if we had not had passage of it who would receive dialysis
and transplantation.
CHAIRMAN PELLEGRINO: Dr. Carson.
DR. CARSON: Thank you both for that very
provocative presentation and Neil, it's good to see you here. I
have several questions but in the interest of time, will limit myself
to one. Dr. Siminoff talked a little bit about something that seems
counter-intuitive and that is that the more information families had
about brain death, the less likely they were to donate. Have you found
that, in fact, where the primary decision maker is a physician, that
the number of donations tends to decrease?
DR. SIMINOFF: When you say, you mean people who are
in health care who have to make those decisions? We've never had
enough data to really — to look at people in that way and divide it
out. It's not necessarily whether people had more or less
information. A lot of those people had the same amount of
information. It was what they took away from that information. So
there were lots of people who just, despite the fact that they had
these discussions about brain death and what it was and they saw
things, you know, x-rays of blood flow and this and that, it just
didn't mean anything to them. They just didn't understand it.
And they may not have understood it because it's
complicated, and a lot of physicians don't understand it. So it
may be that they didn't understand it because they were very
stressed at the time and it was just too much for them to take in.
What seemed to really be important to people was that they understood
not the technical issues of brain death, but they understood that it
was hopeless for this person and this person would never recover. That
was the bottom line, for people whether they understood that, you know,
brain death or not.
Now, it was an interesting finding that when you didn't
really understand brain death and you didn't really know the moment
of death, you were somewhat more likely to donate. And that may have
been a result of the fact that that was just not an important issue for
people. And we actually did a very interesting study which we
published that showed that when we asked the general public about 1300
people what they understood about brain death, they didn't
understand a lot and then when we gave them various scenarios ranging
from people who are classically brain dead, people who are in a —
they're neurologically impaired and they're on life support,
but they're not going to ever be brain dead and then people who are
in persistent vegetative state, at least a third of the public is
willing to donate for people that they know are not technically dead
and that was a very, very interesting finding because in reality there
is a significant number of people that don't care about these
medical definitions. They have personal definitions of personhood and
the soul and a lot of other things that go into it, and so the
medical/technical stuff is just irrelevant for them. So that's the
best answer I can give you.
DR. CARSON: Okay, thank you.
DR. POWE: I know of one study, it's not quite
related, of an individual, I forget his name, who did a study, did a
study of focus groups of physicians about organ donation. He was
interested in disparities, yeah, but what he found is that many of the
physicians and health care professionals had some of the same beliefs,
surprisingly, that the general public did. Now, I don't think he
asked specifically about brain death but it was surprising that they
held some of the views that the general public even though they were
more knowledgeable, you know, about health.
DR. CARSON: And maybe that's the reason that
physicians have such poor procurement rates.
DR. SIMINOFF: That may be.
CHAIRMAN PELLEGRINO: Thank you very much, Dr.
Carson, for your sensitivity of the time constraints under which we
operate. We have now gotten to the point where I think we have to do
some limitations. We have one, two, three, four speakers on the
council who would wish to comment. May I suggest the following; if you
would put forth your questions and ask the respondents to hold off
until you're finished and then you take one or two of those.
We're not going to be able to cover all of them, otherwise we will
cut into the next session after the break.
So if you'll allow me to make an executive decision, I
will do so. We won't have a discussion about it, we will do it
that way. So let us have in order, Dr. Bloom, Dr. Hurlbut, Dr.
Gazzaniga and Dr. McHugh and then you folks respond as you see fit but
brevity is the soul of wit.
DR. BLOOM: I will just make a comment and not ask for a response
because you've spoken to it in partiality but the bottom of
your iceberg concerns me more than the tip that we see. And it
seems to me that the bigger ethical issue for the Council at some
point to consider is when do we begin to campaign for preventive
medicine and self-responsibility in health and avoid to the degree
we can, crises in the future?
CHAIRMAN PELLEGRINO: Thank you, Dr. Bloom. Dr.
Hurlbut?
DR. HURLBUT: Well, actually, I'd like to return to the question
that Leon raised about the crisis and, perhaps we can do that in
later discussions. But it does strike me, looking at the statistics
that it's interesting the particularly the live donations that
they come primarily from people under the age of 50 and yet there
are — the crisis seems to be largely people over 50. And
I just intuitively feel there's something a little worrisome
in that relationship, that the young are being asked to donate to
sustain the elderly population. And being over 50 myself, I —
you know, I feel the weight of it but still something strikes me
as strange.
But I do want to make one comment, and that is since your
statistic said that only 40 percent of people actually have indicated a
willingness to donate, it seems to me there's a place where you
really could make a difference and just a thought, in California we
have driving school. If you get an infraction, you can either pay a
fine or go to driving school. That might provide an opportunity for a
much more comprehensive and sensitive discussion and reflection.
Driving school goes on for something like eight hours and they could
prepare a very well documented case for donation and give people an
opportunity to reflect on both the need for donations and also how the
fact that they're in the driving school indicates that they have
not been driving carefully and that if they reflect on the fact that
they may someday too be disaggregated to save somebody's life, they
may drive more carefully as well as donate more frequently.
CHAIRMAN PELLEGRINO: Dr. Gazzaniga?
DR. GAZZANIGA: I would like to represent the over
65 pro-life group (laughter). One man's crisis is another
man's statistic. Since we have you here, and since you represent
the side of medicine that seems to be seeking increased organs for use,
what I did miss was your specific, if you have, specific
recommendations for how that might come about and then tied to that
question is, do you find various OP organizations at odds sometimes
with UNOS and other organizations that have adopted a different public
view of the nature of this situation?
CHAIRMAN PELLEGRINO: Dr. McHugh.
PROFESSOR McHUGH: I was very interested in what
both of you had to say from the data and I'm very appreciative of
it, but I missed something in your understanding of the problem, not
just this issue of the crisis but it's a very similar issue that we
used to face when people really cared about autopsy rates. When I was
an intern and a resident, if you didn't get an autopsy the chief of
the service was extremely cross with you and he presumed an important
thing, namely that you didn't care enough about that family to win
them over to understand the anonymous benefits that were going to come
from the autopsy were, in fact, part of the relationship that you had
with that family and worked with that family to have them understand.
It wasn't simply a matter of information, in other
words. It was a matter of relationship. And a lot of things that
you're saying today about this issue being a crisis, but also the
idea that there are people out there that are buying and selling these
matters, show me, anyway, that there are problems in recognizing the
personhood that's going on here rather than simply the machinery
that could be replaced like you replace a transmission.
You said for example, somebody said here that nephrologists
don't work with end stage renal disease, so the best people, the
people most interested in this condition of renal disorders aren't
working with the serious patients who could be their best advocates
because they knew them, not just that they knew their kidneys. And
that likewise we also say that the doctors are so busy now that they
can't stop long enough with the persons in the families to give
them — so we bring in these advocates for organ procurement.
I don't think that unless there is an understanding
that you're grappling with matters of personshood, and personhood
here, both from the giver and the receiver, that you're going to do
much better than you already have done. At this rate, I would have
thought it's probably what you're going to get for kidneys and
probably the best you're going to get with livers, until you stop
looking at this in machinery ways, appreciate that the distrust of the
health system has certain coherent reasons for it, people have lots of
reasons for seeing the depersonalizations that are going on in there,
and I don't think that's so much a philosophical matter as a
matter of the system itself and the way we're thinking about these
matters like cars. What do you think about that?
CHAIRMAN PELLEGRINO: Thank you, Paul. Would you
respondents pick one or two of those questions?
DR. SIMINOFF: I guess the last question which gets
the grease, I guess. I think what you said is interesting and
certainly there — the first question or mention, the issues of time,
and those are very real issues and I think that even though there are
many physicians who really would like to sit down and have these
discussions with families, they simply are unable to. I mean, if you
look at what goes on in an ICU, I think there's a tradeoff here.
They say here is a patient that I can't do anything
more. They're dead or they're about to be dead and they need
to make certain decisions. Now, I know that we have traditionally
thought that it's physicians that really have to do with families
and patients, but there are many, many other health care workers.
There are nurses and social workers, and yes, these people from the OPO
that are well-trained, do really care about people and really can
perform these functions.
So I guess when I understand physicians who say to me,
"I care about this issue, I don't really have time for it and
I'm sorry but I just don't," what we've found is that
when you have physicians who are that pressed for time, you're
better off not having them do it, because they don't do a good job
and I mean, I've seen physicians who sort of say, "You know,
here's what's going on, they're brain dead. They could
donate, let me know." Well, that's not a conversation,
that's doing an injustice. So I do think we need to seriously
think that there are other health care professionals that can show
caring and compassion and provide good care to these families in lieu
of physicians.
CHAIRMAN PELLEGRINO: Thank you very much. Dr.
Powe?
DR. POWE: I'd just build a little on that. I
don't think it's been in physicians' training to get much
training in doing this so a lot of them are even uncomfortable with it
and when they're uncomfortable with it, that makes it even more
difficult. The issue you raised about autopsies benefitting, one of
the issues that's not clear that if I donate whether I actually
benefit. I think in the living related one there is more of that,
"I'm benefitting my family." And I think that's one
of the things to consider, you know, is should there be incentives if I
donate and I need something in the future, is somebody going to, you
know, step up to the plate, you know, for me or for my family. And I
think that's one of the issues around incentives.
You know, I guess the other question that has been raised
is how might we make available more organs. Well, I think people have
looked at this, you know, in the cadaveric issue and the living
donation. A lot of people think we should push living donation as far
— that's not even as far as it should be, that, in fact, when
families have an affected individual, they can't find anyone in
their family who would step up or feel comfortable. And so there's
been interventions now that have been tested, trying to be tested in
the living donation category.
And you know, as you know, the biggest thing now is really
whether there should be incentives, whether it's non-monetary or
monetary incentives for cadaveric donation is a big issue and
something, I think, the Committee has to wrestle with.
DR. SIMINOFF: Just one thought about that, for the
first time, living donors surpass by just a little bit the numbers of
donors from deceased donors. So deceased donors is actually a smaller
component. I actually believe that living donation, it's not that
it's not a good thing, but we have to recognize that there are real
risks to the people who are donating and so it seems to me that
we're morally obligated to make the deceased donor system the best
we can so that we can maximize the donors that we do have from the
deceased who, after all, at least according to most of our
understanding do not need those organs any more, so that we can
diminish the risk that we're asking people who are living to
undergo.
So I actually personally believe that although I'm
certainly not against living donors, I think we actually have a moral
obligation to maximize the deceased donor pool so that we can put as
few people at risk as living donors as we can.
CHAIRMAN PELLEGRINO: Dr. Powe, one more, we have just a few
seconds. Go ahead.
DR. POWE: Okay, let me see if I can — the first
comment was a comment about should we be campaigning for more
preventive help and that's what I do, but — and I would applaud
that. However, I don't think that's going to do much in the
next 10 to 20 years. I mean, maybe we can get there. By then we
should do that. We should be looking forward. I think we need a
multi-pronged approach here but there's going to be a lot of
problems between now and when we get there. So I think we have to do
something here and now.
The other comment was about live donations in the younger,
kind of subsidizing the older's health. Interesting. I think in a
live donor it's a different issue because it's often family
members and yeah, you know, my mother just turned 80 if she needed an
organ, would I step up to the plate? I probably would step up to the
plate. So whether that's true in the deceased donor or whether you
even have control over that is an issue. So I think — I'm not
sure there's anything wrong with that in the living donation
category.
CHAIRMAN PELLEGRINO: Dr. Siminoff, one more.
DR. SIMINOFF: Yeah. In terms of that whole issue
about the people who are over 65, I think that being over — as I get
closer to it, I think being over 65 now is surely not what it was 50
years ago. I think people are certainly — despite chronic disease, I
think people are certainly healthier and are leading more active
lives. I think those are issues about rationing. When we initially
rationed dialysis, we had huge problems. We had huge inequities and
I'm uncomfortable with the idea that just because you're 55 or
60 that you're somehow less worthy than if you're 12.
I mean, of course, the death of a 12-year old is a tragedy
but for the family of a 60-year old, the death of a 60-year old can be
equally a tragedy. I don't know how we weigh that and I guess
that's why we have a President's Commission to do that.
DR. POWE: Yeah, and the system today, I mean,
children are preferred. They're more privileged in the current
system in terms of getting transplants and many of the children — most
of the children who have end stage renal disease, you know, eventually
gets transplants. The waiting time is much less for those individuals
and I think that's appropriate.
DR. SIMINOFF: And remember, there are size issues.
So you can't take the kidney or the heart of a six-foot man and put
it in a six-year old child.
CHAIRMAN PELLEGRINO: Dr. Powe, Dr. Siminoff, thank you very,
very much. Council members, thank you also.
(Applause)
CHAIRMAN PELLEGRINO: I want to thank you all for
your forbearance on the time limitations. We will extend the rest
period until 11:00 o'clock.
(A brief recess was taken.)
SESSION 2: ORGAN TRANSPLANTATION AND PROCUREMENT—LITERARY AND PHILOSOPHICAL-ANTHROPOLOGICAL PERSPECTIVES
CHAIRMAN PELLEGRINO: Attention. All right, thank
you very much, those of you who are seated. Thank you very much.
Thank you for reassembling, thank you very much, all the Council
members.
We move to the second session from the empirical data, the
sociological and the numerical and clinical data, we move to another
area from the literary and the anthropological and the philosophical
sense, views of organ transplantation. And I'd like to call on our
first speaker for this next session, Mr. Thomas Lynch, the author of
"The Undertaking, Life Studies from the Dismal Trade and Bodies at
Motion and at Rest." Mr. Lynch.
MR. LYNCH: Well, thank you, Doctor, and thank you for
the invitation to be here. I want to thank Dr. Davis for that invitation
and I was asked to hold court for about a half an hour and then
there will be questions and answers. I'll endeavor to hold
court for a little bit and on the subject of questions and answers,
I should say that I look forward to them so that we can go in the
direction of your interests as well as mine.
I should also say that I cannot be offended. I've
raised teenagers, so I'm thin-skinned, but amply padded so ask
away. (Laughter) I embalm and do sonnets and I'm happy to
entertain conversation between those subjects and if I don't have
an answer, I'll make something up.
But I thought I'd take advantage of the audience and start
by reading a poem since we are considering literary aspects of organ
procurement. And some years ago I was asked to — as part
of my indenture to a British publisher, to do a reading at Guy's
Hospital in Central London in what was called the Old Operating
Theater. It was, I think an 18th Century amphitheatric
room with, you know, few props. The only thing that they had there
was you know, a wooden table with some sawdust, a bucket and blades.
I think maybe this is familiar to the medicos among us but for me
they thought it was particularly apropos, because I'm a funeral
director, they thought I'd be really comfortable there. Don't
you just love them for those types of considerations. So this is
a piece called, "The Old Operating Theater, London, All Souls
Night." It's taken — there's a part of it taken
from that lovely passage in Genesis where Abraham has that
dream about becoming the father of a nation, you'll remember
this. There's the good news, A, he's going to be the father
of a nation, and then the bad news, at least if you're one of
his tribe's people, that everyone must be circumcised, at least
the men. And I always tried to imagine the number of them running
off into the desert on that morning when he first announced this
Old Testament to them.
"To rooms like this old resurrectionists return the bodies
they had disinterred. Fresh corpses so fledgling anatomists could
study origin and insertion points of deltoids, pecs, trapezius and
count the vertebrae, the ball and socket joints and learn the private
parts and Latin names by which the heart become a myocardium, the high
cheekbone a zygoma, the brain less prone to daydream is a cerebellum,
and squirming in their stiff unflinching seats apprentice surgeons
witnessed in the round new methods in advanced colostomy, the
amputation of gangrenous limbs and watched as Viennese lobotomists
banished the ravings of a raving man but left him scarred and drooling
in a way that made them wonder was he much improved. But here the
bloody masters taught dispassionate incisions, who to suture and
remove.
In rooms like this the Greeks and Romans staged their early
dramas. Early Christians knelt and hummed their liturgies when it was
held that prayers and penance were the only potions. Ever since
Abraham guided by God first told his tribesmen of the deal he'd
made, their foreskins for that ancient covenant. Good medicines meant
letting human blood. Good props include the table and the blade. Good
theater is knowing where to cut."
So I read that in part because it introduces us to this
morning's considerations of bodies and body's parts, their uses
and abuses, the issues of function and dysfunction, mortality and
vitality, pathology and personhood, the living and the dead. These are
topics that have always interested me. And the language of these
issues, words like harvest, procurement, consent, donor, recipient and
more lately, seller, buyer, agent, this is the language of the farm and
market, of the foundation and institution and suggests a set of long
established guiding principles or corporate policies and longstanding
ethical standards.
We talk now of future in the cadaveric tissue and organ markets as if
we were talking about crude oil or soy bean futures, and suddenly
we seem, we human beings, to quote from the songwriter Rufus Wainwright,
"to be so many cubic feet of bone and blood and meat and nothing
more." My experience as a funeral director for the past 35
years, as the son of a funeral director for the years before that,
as the brother and — brother of funeral directors and father
of funeral directors now has taught me just the opposite. That
we are more than the sum of our parts. And furthermore, our parts,
our limbs and organs and remains represent more than remnant or
accessory or fragment. When speaking about human bodies the part
is an essential portion, not an accessory, of the whole and it's
precious to the owner whether the owner is the body in its current
incarnation or the surviving bereaved family.
My experience with bodies and the parts of bodies over the past
35 years has taught me that our dead are precious to us because
ours is a species for better or for worse, that has learned to deal
with death, the idea of the thing, by dealing with our dead, the
thing itself. I'm borrowing here, I think from Wallace Stevens
who makes the distinction between the idea of the thing and the
thing itself. And it casts me back in imagination to, depending
on what channel you're watching at night, 40 or 50,000 years
ago when the first human widow awakened in that cave to the dead
lump of protein next to her and said something on the order of,
"My he's very quiet this morning," or words to that
effect.
But depending on the season and the weather, sooner or later she
would begin to sense, actually, she'd being to smel,l that this
stillness was a different stillness than he or she had ever experienced
before. She knew she'd have to do something about it. Ours
is a species that deals with the idea of death by dealing with its
dead. She knew she'd have to leave the cave to him in which
case, I suppose, it would become his tomb. Or maybe she thought
she'd drag him out by the ankles and kick his sorry self over
the cliff, in which case we could call him "consigned to that
oblivio" or maybe she'd build a fire and burn his body,
or maybe she'd scratch a hole in the ground and tip him into
it.
Whatever she did, whatever oblivion she consigned him to 40 or
50,000 years ago, it was the questions that quickened in her looking
into that void that became, I think, the signature of our species
that separates us from rock bass and rhododendron and cocker spaniels
and other living things that die. As someone quite rightly pointed
out and you can try this at home, the numbers are convincing on
this, hovering as they do around 100 percent. But that is a sadness,
whether it's a crisis is for us to discuss. But looking into
whatever oblivion she consigned that first dead thing to, she asked
the standard questions. I hear them asked by widowed people today:
"Is that all there is? Can it happen to me? Why is it cold?
What comes next?"
So ours is a species that for better or for worse, while
the dead do not care and you can try this at home, too. I've spent
a fair amount of time around cadavers, corpses, dead neighbors, dead
friends and family and never once has one of them said anything like,
"I want the blue pinstripe suit or the cherry casket or the mum
plants, please in my behalf." They say nothing. They are mum on
the subject. The dead don't care, you can take that to the bank.
But the dead do matter.
They matter to the living in ways that we're only beginning
to understand. And so part of the considerations here as you discuss
bodies and the parts of bodies, I would encourage you to take on
more of the notion that whether we are talking about the parts of
bodies of dead gangsters, buried maybe in Milford, Michigan, as
we found out last month when they went digging for whatever is left
of whatever remains, whatever might be there of Jimmy Hoffa, at
Hidden Dreams Farms, or whether we are looking for our dead at fresh
kill landfill site after their murder is commingled, their bodies
are commingled with the act of their murderer on September 11th
in our great cities, that the dead are with us. We are all haunted
— properly and happily in some cases — by not only their
memories, but by their remnants. I have seen this not only in consideration
of organs transplanted or tissue donated, I have seen this in how
we consider fetal deaths, expectancies, the whole notion that has
fueled the... our concerns over the abortion and reproductive rights
conflicts in this country over the past 30 years, just like the
ones that are fueling the ones about so-called "assisted suicide,"
are based on the notion of when death happens and when life is.
And there is a difference, as one of your panel pointed out, between
the notion of medical death, metabolic death and the notion of social
death and spiritual death and actual death as far as your family
is concerned, and those are the things this council must wrestle
with when you seek to set forth useful policy. I might know, for
example, that at the end of a process with cremation, we end up
with say 14 pounds of bone fragment and dessicated tissue that we
can put in a box and hand to the family. But when you see the elderly
sister come to claim the ashes of a sister whose own children couldn't
come and get her, when she bears that box like Viaticum, when she
walks out the door, flips the button to open the trunk and then
reconsiders and goes to the back door and opens it up and then thinks
better of it and closes it again, when she goes to the passenger
— front seat passenger door, opens it up, places the box on
the front seat and then clicks a seatbelt around it, you can see
that whether we are remnant or icon or relic is not up to you or
me. It's up to the living that bear us in their memory and
in fact, that bear our mortality because we are mortals, we are
humans. We are tied to this humus, this layer of earth from which
our monuments and our homes and our histories rise out of.
The dead are everywhere. When my father died in Florida many
years ago, my brother and I got on plane to go down and prepare
his body to bring him home to Michigan. And I can remember thinking
as we saw him laid out on the embalming table of the Myers —
or the Anderson Funeral Home in Ft. Myers, Florida, thinking at
first, "This is what my father will look like dead," and
then, "This is my father dead," and then, "This is
maybe what I'll look like when I'm dead," because we
dispose of our dead and then become them. And we do not dispose
of their parts easily.
The market, the retail event involved in organ and tissue procurement
is something that may have medical consequence but to most families
it remains a mystery, tied up, as your Council has rightly put forth,
in issues of personhood, not parts. There's this "just
a shell" theory of how we should relate to dead human bodies.
You hear a lot of it from young clergy and old family friends, well-intentioned
in-laws, folks who are unsettled by the fresh grief of others.
You hear it when you bring a mother and a father in for the first
sight of their dead daughter killed in a car wreck or left out to
rot by some mannish violence. It is proffered as a kind of comfort
in the teeth of what is a comfortless situation, consolation to
the inconsolable. Right between the inhale and exhale of the bone-wracking
sob such hurts produce, some frightened and well-meaning ignoramus
is bound to give out with, "It's okay, it's not her.
That's just a shell."
I once saw an Episcopalian deacon nearly decked by the swift slap
of a mother of a teenager dead of leukemia to whom he had tendered
this counsel. "I'll tell you when it's just a shell,"
the woman said. "For now and until I tell you otherwise, she's
my daughter." The woman was asserting the longstanding right
of the living to declare the dead, dead. Just as we declare the
living alive through baptisms and lovers in love by nuptials, funerals
are the way we close the gap between the death that happens and
the death that matters. It's how we assign meaning to our little
remarkable histories. And the rituals we devise to conduct the
living and the beloved and the dead from one status to another have
less to do with performance than they do with meaning. In a world
where dysfunction has become the operative adjective, a body that
has ceased to work has, it would seem, few useful applications beyond
those we are talking about here this morning. It's dysfunction
more manifest than the sexual and familial forms that fill our tabloids
and talk shows but a body that doesn't work is, in the early
going, the evidence we have of a person who has ceased to be and
a person who has ceased to be is as compelling a prospect as it
was when the neanderthal first dug holes for his dead and set our
species apart from the others.
The bodies of the newly dead are, therefore, not debris or remnant,
nor entirely icon or essence. They are rather changeling, incubates,
hatchlings of a new reality that bear our names and dates, our images
and likenesses, as surely in the eyes and ears of our children and
grandchildren as did words of our birth in the ears of our parents
and their parents. It is wise to treat such new things tenderly,
carefully and with honor.
So I encourage the council as you go to work wrestling with
these difficult issues, that you consider the traffic between the
living and the dead because in most of these situations, there is no
medicine or math, no bottom line or Bible verse, that will explain the
mystery that we behold when we behold someone we love dying or dead. I
know this for a fact, not only because of my professional and personal
experience, because I sense it in the lives of people all around me.
Today as we speak, my sons are conducting the funeral of a
man who died on Sunday in a car wreck near Milford. He has a son who
is two years old and his wife is pregnant with their second son. They
have decided to name this new thing, this yet to be born son after his
dead father. Before he was brought to the funeral hom